DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TECHNETIUM TC 99M MPI MDP

« Back to Dashboard

Clinical Trials for Technetium Tc 99m Mpi Mdp

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00001003	A Study of Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	N/A	To evaluate and compare 3 anti-pneumocystis regimens plus zidovudine (AZT) in persons with advanced HIV disease and T4 cell count < 200 cells/mm3. To establish the range of pentamidine (PEN) deposition in AIDS patients participating in ACTG 021 and ACTG 081. To identify factors (breathing pattern, pulmonary function) that may be important in affecting the actual dose delivered to a given patient. The specific system that is used to deliver PEN to the lungs may determine whether a therapeutically effective dose is attained in the lungs. Therefore, this study will establish the amount of PEN that is deposited in the lungs of patients enrolled in protocols ACTG 021 and ACTG 081, who are being treated with PEN administered from the Marquest Respirgard II nebulizer.
NCT00003654	Diagnostic Study to Identify Sentinel Lymph Nodes in Women With Stage I or Stage II Breast Cancer	Unknown status	UNICANCER	N/A	RATIONALE: Diagnostic procedures, such as blue dye or imaging to identify sentinel lymph nodes, may improve the ability to detect the extent of disease and help plan effective surgery for removing breast tumors. PURPOSE: Diagnostic trial to study the effectiveness of blue dye and an imaging procedure to identify the sentinel lymph node under the arm in women with stage I or stage II breast cancer.
NCT00004705	Study of Uridine Triphosphate (UTP) as an Aerosol Spray for Cystic Fibrosis	Completed	University of North Carolina	N/A	OBJECTIVES: I. Determine the stability of uridine triphosphate (UTP) and examine the metabolism of exogenous nucleotides on airway epithelial surfaces in patients with cystic fibrosis. II. Determine the acute safety and efficacy of aerosolized UTP in children with cystic fibrosis.

Clinical Trial Conditions for Technetium Tc 99m Mpi Mdp

Condition Name

Condition Name for Technetium Tc 99m Mpi Mdp
Intervention	Trials
Breast Cancer	9
Healthy	3
Melanoma	3

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Technetium Tc 99m Mpi Mdp
Intervention	Trials
Breast Neoplasms	12
Carcinoma	10
Syndrome	6

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Technetium Tc 99m Mpi Mdp

Trials by Country

Trials by Country for Technetium Tc 99m Mpi Mdp
Location	Trials
United States	183
Canada	21
United Kingdom	11
Italy	8
France	5

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Technetium Tc 99m Mpi Mdp
Location	Trials
California	14
New York	11
Pennsylvania	11
Minnesota	10
Texas	10

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Technetium Tc 99m Mpi Mdp

Clinical Trial Phase

Clinical Trial Phase for Technetium Tc 99m Mpi Mdp
Clinical Trial Phase	Trials
Phase 4	6
Phase 3	12
Phase 2/Phase 3	1

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Technetium Tc 99m Mpi Mdp
Clinical Trial Phase	Trials
Completed	47
Recruiting	16
Terminated	9

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Technetium Tc 99m Mpi Mdp

Sponsor Name

Sponsor Name for Technetium Tc 99m Mpi Mdp
Sponsor	Trials
National Cancer Institute (NCI)	17
Endocyte	9
Mayo Clinic	8

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Technetium Tc 99m Mpi Mdp
Sponsor	Trials
Other	80
Industry	47
NIH	29

Export unavailable in trial.
Subscribe for complete access.